Role of CD36 rs1761667 AA genotype in the expression of inflammatory cytokines and Parkinson's disease progression: A case-control study in a northern Han Chinese population. (27th July 2022)

• Record Type: Journal Article
• Authors: Li, Chengqian; Hou, Binghui; Li, Xiaoyuan; Yang, Zhengjie; Xie, Anmu
• Is Part Of: Neuroscience letters. Volume 784(2022)
• Publication Date: 2022-07-27
• Subjects: CD36 -- Parkinson's disease -- Gene polymorphism -- Inflammatory cytokines -- Microglia -- Neuroinflammation; AD Alzheimer's disease -- α-syn alpha-synuclein -- CI confidence interval -- HWE Hardy-Weinberg equilibrium -- IBD inflammatory bowel disease -- IL interleukin -- LB Lewy body -- NF-κB nuclear factor-kappa B -- NLRP3 NOD-like receptor family pyrin domain containing 3 -- OR odds ratio -- PCR polymerase chain reaction -- PD Parkinson's disease -- PKCδ protein kinase C-delta -- ROS reactive oxygen species -- TNF-α tumor necrosis factor-alpha -- UV ultraviolet; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2022.136736
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: The CD36 rs1761667 AA genotype may increase susceptibility to Parkinson's disease. The CD36 rs1761667 AA genotype is associated with reduced plasma CD36 levels. Plasma IL-6/1β and TNF-α levels are elevated in patients with PD and AA/GA carriers. IL-6/1β and TNF-α levels are risk factors for PD in a northern Han Chinese population. Abstract: Objective: This study aimed to investigate the effect of CD36 rs1761667 gene polymorphisms on the expression of CD36 and inflammatory cytokines and the progression of Parkinson's disease (PD). Methods: A total of 138 patients with PD (60 men and 78 women) and 132 healthy controls (48 men and 84 women) from a northern Han Chinese population were enrolled in this case–control study. Polymerase chain reaction–restriction fragment length polymorphism was used to detect the CD36 rs1761667 genotype. An enzyme-linked immunosorbent assay was used to determine the expression of CD36, interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α in the plasma. Results: The frequency of the rs1761667 AA genotype was significantly higher in patients with PD than that in healthy controls, suggesting AA genotype to be a risk factor for PD. When compared with those in healthy controls, CD36 levels were significantly lower in patients with PD, whereas IL-6, IL-1β, and TNF-α levels were significantly higher in patients with PD. Furthermore, GA and AA carriers with PD showed lower levels of CD36, and GG, GA, and AA carriers showed higher levels of IL-6, IL-1β, and TNF-α than those in healthy controls. In the PD patient group, AA and GA carriers had lower expression levels of CD36 than GG carriers did, and CD36 levels were lower in AA carriers than in GA carriers. Conversely, AA carriers had elevated expression levels of IL-6 compared with that of GG and GA carriers. Logistic regression analysis revealed that IL-6, IL-1β, and TNF-α levels were risk factors for PD in a northern Han Chinese population. Conclusion: The CD36 rs1761667 AA genotype may increase susceptibility to PD and the expression of inflammatory cytokines.